SKIN
SkinHealth Systems Inc.
SKIN offers stronger fundamentals, but that advantage does not outweigh its weaker overall profile.
UNH
UnitedHealth Group Incorporated
UNH has a slight edge over SKIN overall, supported by lower modeled downside and stronger valuation.
SKIN Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Stable | |
| Strong |
SKIN's balance sheet is currently strong, and its revenue, profitability and cash flow are stable.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
SKIN PE Valuation
SKIN has no meaningful PE right now: it lost money over the past year.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
SKIN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Stable | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect SKIN's losses to shrink, with revenue holding steady. However, they disagree widely on these estimates.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
SKIN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.94 | +$2.12 |
| Q2 2026 | -$3.60 | +$1.66 |
| Q1 2026 | -$2.60 | +$5.26 |
SKIN is still losing money, but far less than before: $1.94 per share over the past year, against $99.60 at its worst in early 2022.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH has the edge over SKIN in the latest year-over-year earnings comparison.
SKIN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $69.2M | -2.1% |
| Q2 2026 | $72.1M | -7.8% |
| Q1 2026 | $64.9M | -6.7% |
| Q4 2025 | $82.4M | -1.3% |
| Q3 2025 | $70.7M | -10% |
| Q2 2025 | $78.2M | -14% |
| Q1 2025 | $69.6M | -15% |
| Q4 2024 | $83.5M | -14% |
SKIN's revenue has slid since its 2023 peak: $69M last quarter, down 2.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 7.2% | +16 points |
| Q2 2026 | 5% | +8.4 points |
| Q1 2026 | -2.8% | +15 points |
| Q4 2025 | 0.2% | +8.8 points |
| Q3 2025 | -8.8% | +19 points |
| Q2 2025 | -3.5% | +21 points |
| Q1 2025 | -17% | +3.6 points |
| Q4 2024 | -8.6% | +10 points |
SKIN has the edge over UNH on profitability, with a higher operating margin.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH has the edge over SKIN on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH's operating margin was 5.8% last quarter, up 2 points from the same quarter a year ago.
SKIN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $11.2M | +16% |
| Q2 2026 | $2.2M | -77% |
| Q1 2026 | -$5.8M | -296% |
| Q4 2025 | $15.1M | -8.2% |
| Q3 2025 | $9.6M | -6.7% |
| Q2 2025 | $9.6M | +63% |
| Q1 2025 | $3M | +$20.1M |
| Q4 2024 | $16.4M | +$21.6M |
SKIN still generates free cash flow, though less than at its 2023 peak: $23M over the past year.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH has the edge over SKIN on cash flow, with more consistent year-over-year improvement.
SKIN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.5% | +30.3K shares |
| 1 year | +2.6% | +166K shares |
| 3 years | -1.9% | -126K shares |
| 5 years | +1032% | +5.9M shares |
SKIN has 7M diluted shares, up 2.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2023 | $30.2M |
| Q4 2022 | $80M |
| Q4 2021 | — |
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over SKIN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
SKIN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.8x | Net Cash |
| Q2 2026 | -13.5x | Net Cash |
| Q1 2026 | -21.9x | Net Cash |
| Q4 2025 | -7,050.7x | Net Cash |
SKIN has the edge over UNH on leverage, with a lower net debt burden relative to earnings.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
SKIN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 53.9 | Neutral |
| Stochastic | 58.5 | Neutral |
SKIN's weekly RSI is 54 (neutral) and its Stochastic is 59 (neutral).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
SKIN PE vs Healthcare Sector
SKIN has no meaningful PE right now: it lost money over the past year.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
SKIN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $12.5 | 28% above |
| 20 week MA | $13.6 | 17% above |
| 50 week MA | $18.1 | 12% below |
| 100 week MA | $25.2 | 37% below |
| 200 week MA | $64.3 | 75% below |
SKIN has bounced recently, but its long-term trend is still down: it's above its 8- and 20-week averages, but 75% below its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over SKIN on trend strength, trading above more of its moving averages.
SKIN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $204.2 | $223.0 | +9.2% |
| 2021 | $223.0 | $463.0 | +108% |
| 2022 | $463.0 | $180.8 | -61% |
| 2023 | $180.8 | $62.2 | -66% |
| 2024 | $62.2 | $32.4 | -48% |
| 2025 | $32.4 | $29.2 | -9.9% |
| 2026 YTD | $29.2 | $16.0 | -45% |
SKIN has finished four years in a row lower, and it's down 45% so far in 2026.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over SKIN on returns for 2026, with the stronger performance.